Straits Times Index
3,345.80 +9.21 (+0.28%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
69,133.52 +1,428.86 (+2.11%) CMC Crypto 200
1,492.87 +24.94 (+1.70%)
Takeda Pharmaceutical Company Limited (TAK)
Pre-market:
| Previous close | 13.03 |
| Open | 13.21 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1400 |
| Day's range | 13.19 - 13.38 |
| 52-week range | 12.77 - 16.39 |
| Volume | |
| Avg. volume | 1,567,880 |
| Market cap | 41.893B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 46.03 |
| EPS (TTM) | 0.29 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 0.64 (4.78%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | 18.27 |
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
Business WireTakeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., May 31, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP. The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for rAD
CNW GroupTakeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY® (maribavir) for the treatment for adults with a post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 With the LOI stage now complete, the provinces and territories may proceed in initiating their individual pro
